Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Gynecologic 3Tumor-Agnostic 2Genitourinary 2Classical hematology 2CNS 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Urologic Diseases 1Urinary Retention 1Prostatic Neoplasms 1Patient Satisfaction 1Hematuria 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tranexamic Acid × Genitourinary × Clear all
NCT01869413 2022-10-04

TACT

Ottawa Hospital Research Institute

Phase 2/3 Completed
354 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04555343 2021-11-05

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

Phase 1/2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Hematuria, Prostatic Neoplasms, Urologic Diseases, Urinary Retention, Patient Satisfaction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡